Paladin Labs Signs Licensing and Distribution Agreement with Japan’s Takeda Pharmaceutical

Montréal- based Paladin Labs Inc. and Takeda Pharmaceutical Company Limited of Osaka, Japan announced that they have entered into a licensing and distribution agreement under which Paladin has granted Takeda an exclusive right to develop and commercialize fomepizole in Japan. Fomepizole, which is marketed and distributed by Paladin under the trademark Antizol in Canada and the US, is used as standard treatment for ethylene glycol and methanol poisonings. Under the terms of the agreement, Paladin will receive from Takeda an undisclosed upfront payment for the product, together with royalty payments based on fomepizole sales in Japan. Paladin Labs is a specialty pharmaceutical company focused on acquiring or in-licensing pharmaceutical products for the Canadian and global markets. Takeda is a research-based company, also focused on pharmaceuticals.